局部晚期鼻咽癌低剂量或高剂量同步放化疗联合调强放疗的倾向性评分匹配全国人群队列研究
该研究在台湾开展倾向性评分匹配的全国人群队列研究,比较低剂量与高剂量顺铂同步放化疗联合调强放疗治疗局部晚期鼻咽癌的结局。共纳入1968例接受同步放化疗联合调强放疗的患者,低剂量组328例、高剂量组1640例。
要点
- 研究纳入1968例局部晚期鼻咽癌患者,低剂量组328例、高剂量组1640例。
- 低剂量或高剂量顺铂同步放化疗联合调强放疗均可作为延长生存的标准治疗。
核心结论
- 低剂量或高剂量顺铂同步放化疗联合调强放疗均可作为延长局部晚期鼻咽癌患者生存的标准治疗。
研究设计与样本
- 在台湾开展倾向性评分匹配的全国人群队列研究,按化疗方案分为高剂量同步放化疗组和低剂量同步放化疗组。
- 共纳入1968例接受同步放化疗联合调强放疗的局部晚期鼻咽癌患者,低剂量组328例、高剂量组1640例。
临床怎么用
- 对于局部晚期鼻咽癌,低剂量或高剂量顺铂同步放化疗联合调强放疗均可作为标准治疗选择以延长生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent low-dose (LD) or high-dose (HD) cisplatin with radiotherapy on nasopharyngeal cancer (NPC). Thus, we conducted a propensity-score-matched, nationwide, population-based cohort study in Taiwan to investigate the outcomes of LD-concurrent chemoradiotherapy (CCRT) or HD-CCRT with intensity-modulated radiotherapy (IMRT) in patients with advanced NPC. METHODS: In this study, patients were categorized into 2 groups according to their chemotherapy regimen: HD-CCRT and LD-CCRT groups. RESULTS: We enrolled 1968 patients (328 and 1640 in the LD-CCRT and HD-CCRT groups, respectively) who had received CCRT with IMRT. According to both univariate and multivariate Cox regression analyses, a hazard ratio (95% confidence interval) of 0.75 (0.54-1.06, P = .103) was derived for the HD-CCRT group. CONCLUSION: LD-CCRT or HD-CCRT with IMRT can be a standard treatment that can prolong the survival of patients with advanced NPC.
引用
- Chen TM, Lin KC, Yuan KS, et al. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study. Radiother Oncol. 2017. PMID: 29277447. doi:10.1016/j.radonc.2017.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。